Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Work In Process for 3 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process rose 12.37% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, up 12.37%, and an annual FY2025 reading of $3.9 million, up 12.37% over the prior year.
  • Work In Process was $3.9 million for Q4 2025 at Catalyst Pharmaceuticals, down from $4.6 million in the prior quarter.
  • Across five years, Work In Process topped out at $5.3 million in Q2 2025 and bottomed at $3.4 million in Q4 2024.
  • Average Work In Process over 3 years is $4.2 million, with a median of $4.1 million recorded in 2024.
  • The sharpest move saw Work In Process decreased 24.67% in 2024, then soared 32.89% in 2025.
  • Year by year, Work In Process stood at $4.6 million in 2023, then fell by 24.67% to $3.4 million in 2024, then increased by 12.37% to $3.9 million in 2025.
  • Business Quant data shows Work In Process for CPRX at $3.9 million in Q4 2025, $4.6 million in Q3 2025, and $5.3 million in Q2 2025.